Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability

Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant

 
• By Dean Rudge
  
Korea
Incheon-based Samsung Bioepis believes there is a 'good opportunity' in the US trastuzumab market • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products